Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genmab A/S
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Net Issuance of Common Stock
-kr3.5B
CAGR 3-Years
-125%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Net Issuance of Common Stock
kr8.2B
CAGR 3-Years
123%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Net Issuance of Common Stock
€29.8m
CAGR 3-Years
-64%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Net Issuance of Common Stock
-kr660k
CAGR 3-Years
N/A
CAGR 5-Years
38%
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Net Issuance of Common Stock
kr17.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Net Issuance of Common Stock
kr81.4m
CAGR 3-Years
-10%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
-3.5B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Net Issuance of Common Stock amounts to -3.5B DKK.

What is Genmab A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
-125%

Over the last year, the Net Issuance of Common Stock growth was -279%. The average annual Net Issuance of Common Stock growth rates for Genmab A/S have been -125% over the past three years .

Back to Top